Sorriso Pharmaceuticals outlines Phase 1b ulcerative colitis data for oral antibody
Private startup Sorriso Pharmaceuticals laid out Phase 1b data at a medical conference last weekend as part of its effort to bring an oral antibody to market for IBD patients. The results come after Sorriso ...
